Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yong-Ching Yang"'
Autor:
Andres McKenzie, Noel Timple, Jessica Friedman, Marcus F. Boehm, Karen Lundgren, Robert Scannevin, Kevin Hong, John Brekken, Adeela Kamal, Francis Burrows, Yong-Ching Yang, John Sensintaffar, David J. Busch, Nanni Huser, Srinivas Rao Kasibhatla, Rachel Powell, Hong Zhang, Laura Neely
Publikováno v:
Molecular Cancer Therapeutics. 8:921-929
Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing cell death, making Hsp90 a target of substantial interest for cancer therapy. BIIB021 is a novel, fully synthetic inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0721b242868c8c12d8116c9dd480a53
https://doi.org/10.1158/1535-7163.mct-08-0758
https://doi.org/10.1158/1535-7163.mct-08-0758
Autor:
Junhua Fan, Daun Chung, Diana Choi, Lin Zhang, Patricia Karjian, Marcus F. Boehm, Roy Grecko, Yong-Ching Yang, Francis Burrows, Gregg Timony, Hong Zhang
Publikováno v:
International Journal of Cancer. 120:918-926
The geldanamycin derivative 17-allyamino-17-demethoxygeldanamycin (17-AAG) is a clinical stage ATP-competitive HSP90 inhibitor that induces degradation of HSP90 client proteins. 17-AAG contains 1 ansamycin moiety and is highly potent in conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac7a2945c6f1ad0548bbb769f124c1b
https://doi.org/10.1002/ijc.22392
https://doi.org/10.1002/ijc.22392
Autor:
Daun Chung, Francis Burrows, Karen Lundgren, Lin Zhang, Marco A. Biamonte, Steven Tsurumoto, Laura Neely, Yong-Ching Yang, Hong Zhang, John Brekken, Junhua Fan
Publikováno v:
Molecular Cancer Therapeutics. 5:1256-1264
The selective heat shock protein 90 (HSP90) inhibitor 17-allyamino-17-demethoxygeldanamycin (17-AAG) is currently in phase I/II clinical studies at numerous institutions. Heretofore, the biomarkers to detect 17-AAG bioactivity (Hsp70, Raf-1, and cycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c86c3e589f6a31a9b990d21a2079b38d
https://doi.org/10.1158/1535-7163.mct-05-0537
https://doi.org/10.1158/1535-7163.mct-05-0537
Autor:
Noel Timple, Rachel Lough, Karen Lundgren, Francis Burrows, Laura Neely, Hong Zhang, Yong-Ching Yang
Publikováno v:
International journal of cancer. 126(5)
17-AAG, the first-generation clinical Hsp90 inhibitor, exhibits promising antitumor activity in clinical studies, but is limited by poor solubility and hepatotoxicity. To pursue compounds with better biopharmaceutical properties, we have developed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3a10c8bcfa472efc4211d673161c88
https://pubmed.ncbi.nlm.nih.gov/19676042
https://pubmed.ncbi.nlm.nih.gov/19676042
Autor:
Hong, Zhang, Yong-Ching, Yang, Lin, Zhang, Junhua, Fan, Daun, Chung, Diana, Choi, Roy, Grecko, Gregg, Timony, Patricia, Karjian, Marcus, Boehm, Francis, Burrows
Publikováno v:
International journal of cancer. 120(4)
The geldanamycin derivative 17-allyamino-17-demethoxygeldanamycin (17-AAG) is a clinical stage ATP-competitive HSP90 inhibitor that induces degradation of HSP90 client proteins. 17-AAG contains 1 ansamycin moiety and is highly potent in conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::75e0d8234eb94cdde89013c9aa6f8333
https://pubmed.ncbi.nlm.nih.gov/17131314
https://pubmed.ncbi.nlm.nih.gov/17131314
Autor:
Marco A. Biamonte, Jiandong Shi, Kevin Hong, David C. Hurst, Lin Zhang, Junhua Fan, David J. Busch, Patricia L. Karjian, Angelica A. Maldonado, John L. Sensintaffar, Yong-Ching Yang, Adeela Kamal, Rachel E. Lough, Karen Lundgren, Francis J. Burrows, Gregg A. Timony, Marcus F. Boehm, Srinivas R. Kasibhatla
Publikováno v:
Journal of medicinal chemistry. 49(2)
Orally active Hsp90 inhibitors are of interest as potential chemotherapeutic agents. Recently, fully synthetic 8-benzyladenines and 8-sulfanyladenines such as 4 were disclosed as Hsp90 inhibitors, but these compounds are not water soluble and consequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2da73f004611c3197e278f58c8174aa
https://pubmed.ncbi.nlm.nih.gov/16420067
https://pubmed.ncbi.nlm.nih.gov/16420067
Autor:
Georgina A. Comin, Elaine J. Derbyshire, Philip E. Thorpe, Julian Belloir, Yong Ching Yang, Shuzhen Li
Publikováno v:
Biochimica et biophysica acta. 1310(1)
A new class of angiogenesis inhibitors consist of a non-anticoagulating derivative of heparin, which binds to vascular endothelial cells, coupled to a steriod (e.g., cortisol) which suppresses endothelial cell division. We linked heparin to a further
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa6a060d1e9895291a9830a47f51a75
https://pubmed.ncbi.nlm.nih.gov/9244180
https://pubmed.ncbi.nlm.nih.gov/9244180
Autor:
Yong-Ching Yang, Elaine J. Derbyshire, Philip E. Thorpe, Jay P. Overholser, Georgina A. Comin, Linda Watkins
Publikováno v:
International journal of cancer. 63(5)
Heparin-steroid conjugates have been prepared by linking a non-anti-coagulating derivative of heparin, which binds to endothelial cells, to an angiostatic steroid, which suppresses endothelial cell division. One such conjugate, heparin adipic hydrazi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f745f7fe23024fa0aa177d90ce62ba
https://pubmed.ncbi.nlm.nih.gov/7591287
https://pubmed.ncbi.nlm.nih.gov/7591287